+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immune Checkpoint Inhibitors for Lung Cancer Market - Global Forecast 2026-2032- Product Image
Immune Checkpoint Inhibitors for Lung Cancer Market - Global Forecast 2026-2032- Product Image
New

Immune Checkpoint Inhibitors for Lung Cancer Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 182 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5666149
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Immune checkpoint inhibitors are transforming lung cancer care by leveraging the body’s immune system, presenting new pathways for clinical and commercial advancement in oncology.

Market Snapshot: Immune Checkpoint Inhibitors for Lung Cancer

The Immune Checkpoint Inhibitors for Lung Cancer Market is experiencing robust growth, climbing from USD 1.32 billion in 2025 to USD 1.52 billion in 2026 and projected to reach USD 3.55 billion by 2032. This trajectory is supported by a CAGR of 15.08%, highlighting strong uptake and expanding clinical integration for these therapies.

Scope & Segmentation

This report provides comprehensive coverage of clinical, operational, and commercial dimensions shaping the immune checkpoint inhibitor market for lung cancer. Segmentation delivers actionable detail on therapeutic applications, delivery channels, and care settings to inform strategic decisions for key stakeholders.

  • Cancer Types: Non-small cell lung cancer (NSCLC)—including non-squamous (adenocarcinoma, large cell) and squamous subtypes—and small cell lung cancer (SCLC)
  • Distribution Channels: Hospital pharmacy, specialty pharmacy, retail pharmacy, online pharmacy
  • Treatment Regimens: Monotherapy, combination with chemotherapy, combination with targeted therapy
  • End Users: Hospitals, oncology clinics, ambulatory surgical centers, home care providers
  • Mechanism of Action: CTLA-4 inhibitors, PD-1 inhibitors, PD-L1 inhibitors, specific agents such as ipilimumab, cemiplimab, nivolumab, pembrolizumab, atezolizumab, durvalumab
  • Line of Therapy: First, second, and third or later lines in clinical and reimbursement settings
  • Regions: Americas, EMEA (Europe, Middle East, Africa), Asia-Pacific

Key Takeaways

  • Immune checkpoint inhibitors have moved from experimental therapy to central roles in lung cancer clinical pathways, requiring cross-disciplinary collaboration in oncology, pulmonology, and supportive care.
  • The integration of combination regimens and biomarker-driven strategies is making clinical development and trial design more complex, driving a need for robust companion diagnostics and targeted evidence-generation plans.
  • Payer and regulatory frameworks are evolving, putting greater emphasis on real-world outcomes, comparative effectiveness, and refined patient selection for reimbursement and approval.
  • Innovation in outpatient care, specialty pharmacy distribution, and digital adherence tools is optimizing patient support and therapy administration, while also challenging manufacturers to adapt logistics and supply approaches.
  • Competitive dynamics are intensifying, with newer entrants focusing on differentiation via combination potential, diagnostic integration, and manufacturing agility, while incumbents leverage established datasets and channel networks.

Tariff Impact

Tariff changes in major markets can disrupt biologics supply chains, raising costs for imported components, single-use disposables, and specialized reagents. Manufacturers and contract partners often adjust sourcing and regional supply strategies to buffer clinical trial timelines and maintain commercial continuity. Administrative delays at borders may complicate clinical research logistics, while incremental cost pressures heighten payer scrutiny and influence reimbursement criteria. These pressures do not alter clinical efficacy but reshape the economic environment for development, deployment, and access.

Methodology & Data Sources

This analysis is underpinned by a rigorous mixed-methods approach. Sources include peer-reviewed clinical studies, regulatory approvals, stakeholder interviews, and operational data from manufacturing and distribution teams. Real-world treatment insights and adoption data are triangulated against trial criteria and national guidelines for a holistic view.

Why This Report Matters

  • Enables senior leaders to benchmark clinical and commercial strategies against evolving market expectations and informs decision-making for R&D, manufacturing, and market entry.
  • Supports optimization of distribution, evidence-generation, and payer engagement plans critical for improving therapy uptake and access across diverse healthcare systems.

Conclusion

Success in the immune checkpoint inhibitor market for lung cancer will require integration of strong clinical evidence, diagnostic innovation, resilient supply networks, and strategic collaborations. Aligning operational execution with stakeholder needs drives both patient outcomes and sustainable commercial performance.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Immune Checkpoint Inhibitors for Lung Cancer Market, by Cancer Type
8.1. Cancer Type
8.1.1. Non-Small Cell Lung Cancer
8.1.1.1. Non-Squamous
8.1.1.1.1. Adenocarcinoma
8.1.1.1.2. Large Cell Carcinoma
8.1.1.2. Squamous
8.1.2. Small Cell Lung Cancer
9. Immune Checkpoint Inhibitors for Lung Cancer Market, by Distribution Channel
9.1. Hospital Pharmacy
9.2. Online Pharmacy
9.3. Retail Pharmacy
9.4. Specialty Pharmacy
10. Immune Checkpoint Inhibitors for Lung Cancer Market, by Treatment Regimen
10.1. Combination Therapy
10.1.1. With Chemotherapy
10.1.2. With Targeted Therapy
10.2. Monotherapy
11. Immune Checkpoint Inhibitors for Lung Cancer Market, by Mechanism Of Action
11.1. CTLA-4 Inhibitor
11.2. PD-1 Inhibitor
11.2.1. Cemiplimab
11.2.2. Nivolumab
11.2.3. Pembrolizumab
12. Immune Checkpoint Inhibitors for Lung Cancer Market, by Line Of Therapy
12.1. First Line
12.2. Second Line
12.3. Third Or Later
13. Immune Checkpoint Inhibitors for Lung Cancer Market, by End User
13.1. Ambulatory Surgical Centers
13.2. Home Care Settings
13.3. Hospitals
13.4. Oncology Clinics
14. Immune Checkpoint Inhibitors for Lung Cancer Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Immune Checkpoint Inhibitors for Lung Cancer Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Immune Checkpoint Inhibitors for Lung Cancer Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Immune Checkpoint Inhibitors for Lung Cancer Market
18. China Immune Checkpoint Inhibitors for Lung Cancer Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. AbbVie Inc.
19.6. AstraZeneca plc
19.7. Bayer AG
19.8. BeyondSpring Pharmaceuticals Inc.
19.9. BioLineRx Ltd.
19.10. BridgeBio Inc.
19.11. Bristol-Myers Squibb Company
19.12. Celgene Corporation
19.13. F. Hoffmann-La Roche AG
19.14. Genentech, Inc.
19.15. IQVIA Inc.
19.16. Jazz Pharmaceuticals
19.17. Mirati Therapeutics Inc.
19.18. Ono Pharmaceutical Co. Ltd
19.19. Philogen S.p.A.
List of Figures
FIGURE 1. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 96. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 97. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 98. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 143. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 145. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 146. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 147. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
TABLE 148. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 149. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 150. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 151. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 152. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 153. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 154. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 163. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 165. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 166. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 168. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 169. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 170. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 171. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
TABLE 172. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 174. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 175. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 176. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 177. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 178. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 185. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 186. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 188. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 189. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 190. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 191. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 192. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 194. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 195. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 196. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
TABLE 197. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 198. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 199. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 200. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 201. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 202. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 203. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 204. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 205. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 206. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 207. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 208. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
TABLE 209. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 210. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 211. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 212. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 213. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 214. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 215. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 228. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 229. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 230. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 231. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 232. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
TABLE 233. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 234. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 235. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 236. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 237. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 238. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 239. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 240. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 241. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 242. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 243. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 244. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
TABLE 245. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 246. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 247. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 248. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 249. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 250. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 251. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 252. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 253. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 254. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 255. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 256. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
TABLE 257. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 258. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 259. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
TABLE 260. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 261. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
TABLE 262. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Immune Checkpoint Inhibitors for Lung Cancer market report include:
  • AbbVie Inc.
  • AstraZeneca plc
  • Bayer AG
  • BeyondSpring Pharmaceuticals Inc.
  • BioLineRx Ltd.
  • BridgeBio Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • IQVIA Inc.
  • Jazz Pharmaceuticals
  • Mirati Therapeutics Inc.
  • Ono Pharmaceutical Co. Ltd
  • Philogen S.p.A.

Table Information

Report AttributeDetails
No. of Pages182
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.52 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.55 Billion
Compound Annual Growth Rate15.0%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Lung Cancer Drugs Market - Global Forecast 2026-2032 - Product Image

Lung Cancer Drugs Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Lung Cancer Treatment Market - Global Strategic Business Report - Product Image

Lung Cancer Treatment Market - Global Strategic Business Report

  • Report
  • 373 Pages
  • Global
From
Lung Cancer Therapeutics Market - Global Forecast 2026-2032 - Product Image

Lung Cancer Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Non-small Cell Lung Cancer Therapeutics Market - Global Forecast 2026-2032 - Product Image

Non-small Cell Lung Cancer Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report 2025 - Product Image

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.